Physician profile
Mohammed Samiuddin
NPI 1215152442
$1,438.40
in general payments reported to CMS, 2019-2025
20 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $214 · 2022: $243 · 2023: $551 · 2024: $321 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $981.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $208.41 | 2021-2024 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $193.81 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $193.67 | 2021-2024 | Shingrix, Arexvy, Bexsero |
| Astellas Pharma US INC | $149.39 | 2021-2023 | Myrbetriq |
| Sumitomo Pharma America, INC. | $116.55 | 2023-2025 | Gemtesa |
| Abbott Laboratories | $101.32 | 2022-2024 | Freestyle Libre 3 |
| Stryker Corporation | $63.06 | 2024 | Mako |
| Pfizer INC. | $60.48 | 2023-2024 | |
| Biogen, INC. | $56.80 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.05 | 2021-2023 | Jardiance |
| Sanofi Pasteur INC. | $48.94 | 2023-2024 | |
| Sunovion Pharmaceuticals INC. | $44.43 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.30 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $20.73 | 2023 | Dificid |
| Otsuka America Pharmaceutical, INC. | $19.36 | 2023 | Rexulti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17.77 | 2024 | Mounjaro |
| Dynavax Technologies Corporation | $17.17 | 2022 | |
| Dexcom, INC. | $16.72 | 2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $15.77 | 2025 | |
| Lundbeck LLC | $15.67 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Samiuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.